Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Talazoparib + ZN-c3|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Talazoparib||Talzenna||BMN673||PARP Inhibitor (Pan) 26||Talzenna (talazoparib) is an inhibitor of PARP1 and PARP2, which prevents the DNA repair of single strand DNA breaks, thus causing the accumulation of DNA strand breaks, genomic instability and apoptosis, and leads to lethality in homologous recombination repair deficient cells (PMID: 28242752). Talzenna (talazoparib) is FDA approved for use in patients with ERBB2 (HER2)-negative breast cancer harboring deleterious or suspected deleterious germline BRCA mutations (FDA.gov).|
|ZN-c3||ZNc3|ZN c3||WEE1 Inhibitor 5||ZN-c3 is a small molecular inhibitor of WEE1 and inhibition of WEE1 increases DNA damage in cancer cells to induce programmed cell death (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04158336||Phase Ib/II||ZN-c3 Talazoparib + ZN-c3 Pembrolizumab + ZN-c3||A Study of ZN-c3 in Participants With Solid Tumors||Recruiting||USA||0|